| 723898 |
JOURNAL FOR IMMUNOTHERAPY OF CANCER |
Cystathionine β-synthase mediated PRRX2/IL-6/STAT3 inactivation suppresses Tregs infiltration and induces apoptosis to inhibit HCC carcinogenesis |
2021-08-01 |
10.1136/jitc-2021-003031 |
Zhou Yu-Fu, Song Shu-Shu, Tian Meng-Xin, Tang Zheng, Wang Han, Fang Yuan, Qu Wei-Feng, Jiang Xi-Fei, Tao Chen-Yang, Huang Run, Zhou Pei-Yun, Zhu Shi-Guo, Zhou Jian, Fan Jia, Liu Wei-Ren, Shi Ying-Hong |
| 723897 |
JOURNAL FOR IMMUNOTHERAPY OF CANCER |
CXCR6 is required for antitumor efficacy of intratumoral CD8+ T cell |
2021-08-01 |
10.1136/jitc-2021-003100 |
Wang Binglin, Wang Yi, Sun Xiaofan, Deng Guoliang, Huang Wei, Wu Xingxin, Gu Yanghong, Tian Zhigang, Fan Zhimin, Xu Qiang, Chen Hongqi, Sun Yang |
| 723896 |
JOURNAL FOR IMMUNOTHERAPY OF CANCER |
CARs and beyond: tailoring macrophage-based cell therapeutics to combat solid malignancies |
2021-08-01 |
10.1136/jitc-2021-002741 |
Abdin Shifaa M., Paasch Daniela, Morgan Michael, Lachmann Nico |
| 723895 |
JOURNAL FOR IMMUNOTHERAPY OF CANCER |
Assessing tumor heterogeneity: integrating tissue and circulating tumor DNA (ctDNA) analysis in the era of immuno-oncology - blood TMB is not the same as tissue TMB |
2021-08-01 |
10.1136/jitc-2021-002551 |
Fridland Stanislav, Choi Jaeyoun, Nam Myungwoo, Schellenberg Samuel Joseph, Kim Eugene, Lee Grace, Yoon Nathaniel, Chae Young Kwang |
| 723894 |
JOURNAL FOR IMMUNOTHERAPY OF CANCER |
Dual PD-L1 and TGF-b blockade in patients with recurrent respiratory papillomatosis |
2021-08-01 |
10.1136/jitc-2021-003113 |
Robbins Yvette, Friedman Jay, Clavijo Paul E, Sievers Cem, Bai Ke, Donahue Renee N, Schlom Jeffrey, Sinkoe Andrew, Hinrichs Christian S, Allen Clint, Abdul Sater Houssein, Gulley James L, Norberg Scott |
| 723893 |
JOURNAL FOR IMMUNOTHERAPY OF CANCER |
Phase I/II trial of a long peptide vaccine (LPV7) plus toll-like receptor (TLR) agonists with or without incomplete Freund’s adjuvant (IFA) for resected high-risk melanoma |
2021-08-01 |
10.1136/jitc-2021-003220 |
Patel Sapna P, Petroni Gina R, Roszik Jason, Olson Walter C, Wages Nolan A, Chianese-Bullock Kimberly A, Smolkin Mark, Varhegyi Nikole, Gaughan Elizabeth, Smith Kelly T, Haden Kathleen, Hall Emily H, Gnjatic Sacha, Hwu Patrick, Slingluff Craig L |
| 723892 |
JOURNAL FOR IMMUNOTHERAPY OF CANCER |
Integrated analysis of a phase 2 study of cemiplimab in advanced cutaneous squamous cell carcinoma: extended follow-up of outcomes and quality of life analysis |
2021-08-01 |
10.1136/jitc-2021-002757 |
Rischin Danny, Khushalani Nikhil I, Schmults Chrysalyne D, Guminski Alexander, Chang Anne Lynn S, Lewis Karl D, Lim Annette M, Hernandez-Aya Leonel, Hughes Brett G M, Schadendorf Dirk, Hauschild Axel, Thai Alesha A, Stankevich Elizabeth, Booth Jocelyn, Yoo Suk-Young, Li Siyu, Chen Zhen, Okoye Emmanuel, Chen Chieh-I, Mastey Vera, Sasane Medha, Lowy Israel, Fury Matthew G, Migden Michael R |
| 723891 |
JOURNAL FOR IMMUNOTHERAPY OF CANCER |
CD4+ T cell and M2 macrophage infiltration predict dedifferentiated liposarcoma patient outcomes |
2021-08-01 |
10.1136/jitc-2021-002812 |
Schroeder Brett A, LaFranzo Natalie A, LaFleur Bonnie J, Gittelman Rachel M, Vignali Marissa, Zhang Shihong, Flanagan Kevin C, Rytlewski Julie, Riolobos Laura, Schulte Brian C, Kim Teresa S, Chen Eleanor, Smythe Kimberly S, Wagner Michael J, Mantilla Jose G, Campbell Jean S, Pierce Robert H, Jones Robin L, Cranmer Lee D, Pollack Seth M |
| 723890 |
JOURNAL FOR IMMUNOTHERAPY OF CANCER |
Multicenter phase II trial (SWOG S1609, cohort 51) of ipilimumab and nivolumab in metastatic or unresectable angiosarcoma: a substudy of dual anti-CTLA-4 and anti-PD-1 blockade in rare tumors (DART) |
2021-08-01 |
10.1136/jitc-2021-002990 |
Wagner Michael J, Othus Megan, Patel Sandip P, Ryan Chris, Sangal Ashish, Powers Benjamin, Budd G Thomas, Victor Adrienne I, Hsueh Chung-Tsen, Chugh Rashmi, Nair Suresh, Leu Kirsten M, Agulnik Mark, Sharon Elad, Mayerson Edward, Plets Melissa, Blanke Charles, Streicher Howard, Chae Young Kwang, Kurzrock Razelle |
| 723889 |
JOURNAL FOR IMMUNOTHERAPY OF CANCER |
Not all hematopoietic growth factors are created equal: should we gain information for their use with immunotherapy? |
2021-08-01 |
10.1136/jitc-2021-003154 |
Bossi Paolo, Gurizzan Cristina, Lorini Luigi, di Mauro Pierluigi, Sardini Chiara, Merlano Marco |
